Letters

hemagglutinin disease induced by rituximab therapy Cold hemagglutinin disease is achronic hemolytic anemia that is refractory to the usual treatments for hemolytic anemia mediated by a warm-reactive antibody; it may be associated with a low-grade lymphoma. Two pre-vious case reports point to a possible role for this agent in the treatment of cold hemagglutinin disease.1,2 Ritux-imab is an anti-CD20 monoclonal anti-body of proven efficacy in the treat-ment of low-grade B-cell lymphomas.3 We report a remission of cold hemag-glutinin disease in response to single